Evaluation of lung lavage in meconium aspiration syndrome
A randomised controlled trial of therapeutic lung lavage to reduce the duration of respiratory support required by ventilated newborn infants with meconium aspiration syndrome (MAS)
A/Prof Peter Dargaville
66 participants
Mar 1, 2003
Interventional
Conditions
Summary
Meconium aspiration syndrome (MAS) is a complex disease of the newborn lung that can cause life-threatening respiratory distress very soon after birth. Current management consists mainly of providing supportive care, rather than removing meconium from the lung to hault or slow disease progression. This multicentre randomised controlled trial will test whether therapeutic lung lavage, using a dilute surfactant preparation, improves outcomes in infants with severe MAS. The study will include a total of 66 newborn infants, who are receiving mechanical ventilation because of MAS. The main outcome measure will be duration of respiratory support; secondary outcomes will be duration of oxygen therpay; duration of hospitalisation, and evidence of chronic lung disease.
Eligibility
Inclusion Criteria1
- Neonates (males and females)with confirmed diagnosis of meconium aspiration syndrome with all of the following:1. birth weight >2.0kgs, gestation >36 weeks.2. <24 hours of age3. ventilated with mean airway pressure >/= 12 cm H2O4. Alveolar-arterial oxygen difference >/= 450 mmHg
Exclusion Criteria1
- Known or suspected cardiac abnormality. Severe hypoxic ischaemic encephalopathy or congenital anomaly (ie, withdrawal of treatment being considered). Intractable cardiorespiratory instability.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Lung lavage with 30 ml/kg surfactant solution (5mgs/ml), administered in 2 aliquots, each lasting 1 minute (under 10 minutes for entire procedure), within 24 hours after birth.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000290594